• Home
  • Ponatinib 45mg
  • Ponatinib 45mg

Ponatinib 45mg

52071

Ponatinib is used for chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia when the disease has a T315I mutation or when other tyrosine kinase inhibitors are not suitable.

It is also used with chemotherapy for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia in some countries.

Usual adult dose range: 10mg to 45mg once daily, with the starting dose and later reduction based on the type of leukaemia, response, and risk of blood-vessel side effects.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.